Holen Sie sich die Stockscreener-App
19.62
0.30%
-0.07
Schlusskurs vom Vortag:
$19.69
Offen:
$19.62
24-Stunden-Volumen:
588.91K
Relative Volume:
0.35
Marktkapitalisierung:
$2.88B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-6.8842
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
+10.03%
1M Leistung:
+30.69%
6M Leistung:
+34.04%
1J Leistung:
-21.35%
1-Tages-Spanne:
$19.19
$19.87
1-Wochen-Bereich:
$17.90
$20.61
52-Wochen-Spanne:
$10.57
$25.48
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
19.61 | 2.89B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Technical Reactions to DNLI Trends in Macro Strategies - news.stocktradersdaily.com
Denali enters into a $275M funding deal with Royalty Pharma - MSN
Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy - Indian Pharma Post
Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance
Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance
BTIG Research Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
3,947,387 Shares in Denali Therapeutics Inc. $DNLI Acquired by Norges Bank - MarketBeat
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch By Investing.com - Investing.com South Africa
Denali Therapeutics (MUN:4DN) Price Target Decreased by 15.88% to 28.11 - Nasdaq
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start - inkl
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch - Investing.com Nigeria
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating - marketscreener.com
BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating - 富途牛牛
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Transcript : Denali Therapeutics Inc.Analyst/Investor Day - MarketScreener
Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement - marketscreener.com
Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement - TradingView
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
Denali Therapeutics secures $275M royalty funding deal - MSN
Denali Therapeutics Secures $275M Royalty Funding Deal - TipRanks
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com India
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - Markets Financial Content
How Denali Therapeutics Inc. (4DN) stock reacts to stronger dollar2025 Trading Volume Trends & Daily Stock Trend Watchlist - Newser
Why Denali Therapeutics Inc. (4DN) stock appeals to dividend investorsJuly 2025 Reactions & Real-Time Stock Movement Alerts - Newser
Fisher Asset Management LLC Raises Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
Edgestream Partners L.P. Acquires New Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI) - Seeking Alpha
What technical patterns form on Denali Therapeutics Inc. (4DN) stock chartsQuarterly Risk Review & Expert Curated Trade Setup Alerts - Newser
How Denali Therapeutics Inc. (4DN) stock performs in easing cyclesJuly 2025 Setups & Safe Swing Trade Setup Alerts - Newser
Denali Therapeutics (DNLI) Stock Analysis Report | Financials & Insights - Benzinga
Denali Therapeutics Shows Rising Price Performance With Jump To 83 RS Rating - Investor's Business Daily
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
What risks investors should watch in Denali Therapeutics Inc. stockTrade Volume Report & Free Growth Oriented Trading Recommendations - BỘ NỘI VỤ
Groupama Asset Managment Buys 31,043 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flowsJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - BỘ NỘI VỤ
Denali Therapeutics announces board and leadership changes By Investing.com - Investing.com Nigeria
Transcript : Denali Therapeutics Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 08 - MarketScreener
Trading the Move, Not the Narrative: (DNLI) Edition - news.stocktradersdaily.com
Published on: 2025-11-28 01:22:18 - BỘ NỘI VỤ
Is Denali Therapeutics Inc. stock a good choice for value investorsMarket Weekly Review & Daily Volume Surge Trade Alerts - moha.gov.vn
Geode Capital Management LLC Grows Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Growth Recap: Is Denali Therapeutics Inc. stock positioned for digital transformationJuly 2025 Price Swings & AI Optimized Trading Strategy Guides - BỘ NỘI VỤ
Will Denali Therapeutics Inc. stock reach all time highs in 2025Market Sentiment Summary & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Segall Bryant & Hamill LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):